Effects of beclamide on isolation-induced aggression and locomotor activity in mice
- 1 December 1988
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Pharmacy and Pharmacology
- Vol. 40 (12) , 891-893
- https://doi.org/10.1111/j.2042-7158.1988.tb06297.x
Abstract
The anti-aggressive effects of orally administered beclamide (N-Benzyl-β-chloropropionamide) have been studied in male albino mice which were individually isolated for a 28-day period. Beclamide (50–250 mg kg−1 p.o.) caused an overall dose-dependent increase in the attack onset latency, a reduction in the percentage of animals attacking and the mean number of attacks/animal for this model of aggression. In addition, the highest dose of beclamide (250 mg kg−1 p.o.) did not significantly modify locomotor activity in mice. It was concluded that beclamide induced anti-aggressive effects at non-sedative doses. This anti-aggressive action was thought be at least partially mediated, through a beclamide-induced release of 5-HT from presynaptic sites.This publication has 8 references indexed in Scilit:
- Comparison of the influence of the opiate delta receptor antagonist, ICI 154, 129, and naloxone on social interaction and behaviour in an open fieldNeuropharmacology, 1984
- Behavioural examinations of the anti-aggressive drug FluprazineBehavioural Brain Research, 1983
- The Measurement of Aggression in the LaboratoryPublished by Springer Nature ,1981
- Piperoxane reduces the effects of clonidine on aggression in mice and on noradrenaline dependent hypermotility in ratsEuropean Journal of Pharmacology, 1978
- Anti-aggressive action of dopamine-β-hydroxylase inhibitors in miceJournal of Pharmacy and Pharmacology, 1976
- A DOUBLE-BLIND CROSS-OVER STUDY OF THE EFFECT OF BECLAMIBE (NYDRANE) ON BEHAVIOUR DISORDERS IN THE SEVERELY MENTALLY HANDICAPPEDThe British Journal of Mental Subnormality, 1974
- OBSERVATIONS ON THE USE OF BECLAMIDE (NYDRANE)IN A CHILD PSYCHIATRIC CLINICThe Journal of Mental Subnormality, 1970
- N-BENZYL-β-CHLOROPROPIONAMIDE (HIBICON®)A.M.A. Archives of Neurology & Psychiatry, 1952